Oncology Molecular Diagnostics Market to Reach US$ 6.46 Billion by 2033, Driven by Precision Oncology, and Accelerating Biomarker-Based Therapies - According to DataM Intelligence

AUSTIN, Texas and TOKYO, Nov. 18, 2025 /PRNewswire/ -- DataM Intelligence announces the latest insights into the rapidly transforming Oncology Molecular Diagnostics Market, which increased from US$3.59 billion in 2023 to US$3.79 billion in 2024, and is projected to achieve US$6.46 billion by 2033, expanding at a CAGR of 6.2% during the forecast period. As global cancer incidence rises and precision oncology becomes standard clinical practice, the molecular diagnostics segment is emerging as a critical enabler of personalized treatment decisions, early detection, recurrence monitoring, and optimized therapeutic selection.

The oncology molecular diagnostics landscape is undergoing a profound shift-driven by next-generation sequencing (NGS), liquid biopsy adoption, FDA-approved companion diagnostics, multi-cancer early detection (MCED) innovation, and a strong pipeline of novel oncology therapeutics requiring biomarker-guided testing. Each of these factors is reshaping clinical workflows across hospitals, clinical laboratories, and specialty cancer centers worldwide.

Precision-Oncology Adoption and Technology Expansion Accelerate Global Market Growth

The transformation of cancer care toward personalized therapies is significantly increasing the demand for molecular testing platforms. Cancer treatment decisions are now routinely anchored in genomic alterations, such as EGFR, ALK, ROS1, BRCA1/2, BRAF, KRAS, HER2, and emerging biomarkers like MET exon 14 skipping, RET, NTRK fusions, and tumor mutational burden (TMB).

By technology type, the market is dominated by PCR, owing to its affordability, high-throughput screening capabilities, and routine integration into hospital laboratories for actionable biomarker detection. However, NGS is the fastest-growing technology, supported by the industry's shift toward multi-gene panels, whole-genome sequencing (WGS), and liquid biopsy-based solutions. In situ hybridization (ISH) and other platforms continue to provide value in targeted diagnostics and histopathology-guided testing.

On the basis of products, reagents hold the majority share, driven by the recurring nature of consumable usage in PCR and NGS workflows. Instruments-including automated sequencing systems and digital PCR platforms-remain essential capital investments for advanced oncology research centers. Software is rapidly becoming indispensable, with AI-driven genomic analysis, variant interpretation tools, and clinical decision-support platforms streamlining the complexities of multi-omic data.